Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levocetirizine + montelukast
- Development stage
- Unknown
- Lead developer
- Indi Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Viznil** is an Indi Pharma prescription fixed-dose combination of **levocetirizine** and **montelukast**. Levocetirizine is a selective histamine H1-receptor antagonist that reduces histamine-mediated allergic symptoms, while montelukast antagonizes cysteinyl leukotriene receptor 1 to reduce leukotriene-driven airway and nasal inflammation. Viznil tablets are marketed in India containing levocetirizine 5 mg plus montelukast 10 mg for allergic rhinitis and associated allergy symptoms. ([1mg.com](https://www.1mg.com/drugs/viznil-tablet-141516))
- Brand names
- Viznil
02
Targets
CYSLTR1 (Cysteinyl-leukotriene type 1 receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on levocetirizine + montelukast.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levocetirizine + montelukast.